Celltrion Sees Sales Dip In Q3
As Company Sees Pro-Biosimilar Policies Offering A Boost In US
Executive Summary
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
You may also be interested in...
Celltrion Eyes Price Advantage For ‘Latecomer’ Bevacizumab
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.
Celltrion’s COVID-19 Treatment Regdanvimab Is Approved In Korea
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.